Similar companies
Income Statement (NONE)
| Q4 '25 | QoQ | |
|---|---|---|
| Revenue | 4.71B | 5.2% |
| Gross Profit | 2.66B | 15.2% |
| Cost of Revenue | 2.06B | 5.5% |
| Operating expense | 2.35B | 65.5% |
| Net Income | 480M | 10.9% |
| EBITDA | 426M | 61.4% |
Balance Sheet (NONE)
| Q4 '25 | QoQ | |
|---|---|---|
| Total Assets | 40.7B | 2.2% |
| Total Liabilities | 32.8B | 0.7% |
| Total Equity | 7.91B | 9.2% |
| Shares Outstanding | 1.17B | 0.8% |
Cash Flow (NONE)
| Q4 '25 | QoQ | |
|---|---|---|
| Cash from operations | 1.45B | 293.6% |
| Cash from investing | -118M | 187.6% |
| Cash from financing | 39M | 108.5% |
EPS
Financial Highlights for Teva Pharmaceutical in Q4 '25
Teva Pharmaceutical reported a revenue of 4.71B, which is a 5.2% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.66B, marking a 15.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.06B, a -5.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 2.35B, showing a 65.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 480M, showing a 10.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 426M, showing a -61.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Teva Pharmaceutical with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
